Lawmakers moving to relax FDA conflict rules

Fresh signs are appearing that indicate lawmakers will agree to relax the conflict-of-interest rules that have been hampering the FDA's ability to recruit experts for crucially important advisory committees. A congressional staffer tells Reuters there's a good chance that the issue will be addressed in the final FDA user fee bill. The agency reports that there are vacancies on about one in four of their committees, which vote on whether or not a drug should be approved. The agency moved to prevent experts with financial ties to drug companies following the scandal over Vioxx. Story

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.